This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Biopharmaceutical Contract Manufacturing Market

Market Insights on Biopharmaceutical Contract Manufacturing covering sales outlook, demand forecast & up-to-date key trends

Biopharmaceutical Contract Manufacturing Market By Platform (Mammalian and Microbial), Product (Growth Factors, Interferons, Monoclonal Antibodies, Recombinant Hormones, Vaccines, Insulin and Others), Application (Clinical and Commercial) & Region - Forecast to 2022 - 2029

Biopharmaceutical Contract Manufacturing Market Snapshot (2022-2029)

[221 Pages Report] The global biopharmaceutical contract manufacturing market was valued at around US$ 8.4 Bn in 2021 and is anticipated to progress at a CAGR of 10.5% to reach US$ 18.7 Bn by 2029.

Data Points

Market Insights

Market Value 2021

US$ 8.4 Bn

Market Value 2022

US$ 9.3 Bn

Market Value 2029

US$ 18.7 Bn

CAGR 2022-2029

10.5%

Market Share of Top 5 Countries

59.5%

The continuous growth in life science research segment, increased R&D funding and development of various pharmaceutical products in various countries across the globe has added significantly to the growth of biopharmaceutical contract manufacturing market.

The biopharmaceutical contract manufacturing market holds less than 1% of the global contract manufacturing market in 2021 which is valued at nearly 2300 Bn.

In biopharmaceutical contract manufacturing market, a large number of local players as well as established players are significantly showing interest in either conducting biologic drug based research and development or performing bio-manufacturing processes in different countries, besides marketing their own products there.

Furthermore, the production of vaccines, biosimilars, recombinant proteins and monoclonal antibodies etc., using various technologies has been undertaken by utilizing outsourcing strategy by various manufacturers.

On the other hand, the virtual biotechnology companies with early clinical products uses outsourcing strategy wherein they collaborate with CMOs with smaller facilities for clinical supply at initial stage. Later on, they switch the production to another CMO who is capable of doing production in large batches and is enough experienced in moving products through the clinical phases. For early-stage projects, big biopharmaceuticals companies approach small CMOs. For commercial products, companies tie up with top tier CMO with expertise in vials and who have experience with the FDA.

To meet customer needs, biopharmaceutical companies are entering into various contract manufacturing agreements with contract manufacturing organization (CMO) and Contract manufacturing and development organization (CDMO).

Considering this, it is estimated for the biopharmaceutical contract manufacturing market to grow significantly over the forecast duration.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

10.62%

H1, 2022 Projected

10.62%

H1, 2022 Outlook

10.62%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 10 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 24 ↓

According to FMI, the biopharmaceuticals contract manufacturing market will drop in H1-2022(O) when compared with H1-2021 by 24 basis point share (BPS). Some of the main reasons for the deterioration in BPS are greater production time, higher costs, risk of intellectual property exchange, and lack of communication channels between biopharma companies and contract manufacturing organizations.

The growth rates and development possibilities of the global biopharmaceuticals contract manufacturing market are compared by FMI. The market is influenced by quality control, drug stability studies, regulations, and the impact of macro and industrial variables. This, in turn, is expected to affect the market growth rate in the H1-2022 outlook period to show a dip by nearly 10 BPS when compared with H1-2022 projected period.

While the biopharmaceutical industry has made significant progress, the contract manufacturing and development organisation (CDMO), which develops and manufactures drug substances for biopharmaceutical companies, has grown at the same time, demonstrating a pharmaceutical industry ecosystem that is a horizontal division model of drug research by pharmaceutical and biotech organisations, along with drug manufacture by CDMOs, and is a key driving factor in this sector.

Reduction in sourcing and production costs conversely provide a lucrative growth impact on the biopharmaceuticals contract manufacturing market.

Sales Analysis of Biopharmaceutical Contract Manufacturing from 2012 to 2021 Vs Market Outlook for 2022 to 2029

Sales of biopharmaceutical contract manufacturing market grew at a CAGR of 9.5% between 2012 and 2021.

Biopharmaceuticals contract manufacturing firms play an important role in commercial manufacturing as well as late clinical phase of biologics production. Big pharma companies have limited capacity for biologics production. This incapability leads towards outsourcing of biologics production, which is leading to the growth in the biopharmaceutical contract manufacturing market.

Biopharmaceutical Contract Manufacturing Market Download Report Brochure

The growth of the biopharmaceutical contact manufacturing industry globally is also driven by strong biologics pipeline that fuel the demand for these CMOs (Contact Manufacturing Organizations). A large number of biotech patents are applied every year and this tends to be growing at 23% annually. Nearly 1500 biomolecules are currently under clinical trials, targeting more than 100 types of diseases, the biologics have shown two times higher success rate as compared to small-molecule products.  The current biologics-development pipeline thus, supports an outlook of continued healthy growth.

The market is expected to expand at a considerable growth rate over the next seven years at a CAGR of close to 10.5% from 2022 to 2029.

What are the Key Opportunities Biopharmaceutical Contract Manufacturing?

Key players acting in this market are opting for inorganic growth strategies to boost their earnings and grow market share by way of providing integrated solutions to customers. While few companies are undertaking merger and acquisitions to grow their consumer base, others are involved in aggressive expansion of their product/services/capabilities through strategic alliances. Furthermore, integration strategy of acquiring manufacturing facilities from large pharmaceutical companies is being adopted as another key strategy.

For instance, In July 2020, Fujifilm acquired the Biogen’s large-scale bio-manufacturing facility for US$ 890 million. Similarly, In July 2021, AbbVie Company acquired Allergen. This acquisition helped AbbVie expand its global operations in order to supply end-to-end drug substance and product to manufacturing partners of AbbVie. The contract manufacturing services offers topical creams and ointments, biologics fill-finish, sterile ophthalmic ointments and custom API.

Additionally, many organizations are focusing on reducing the overall operational cost associated with R&D and commercialization of a drug, by looking out for outsourcing options to CMOs. Outsourcing at a later stage of clinical development through identification and appointment of a strategic partner could improve efficiencies all along the value chain.

The CDMO & CMO business model is emerging as a key differentiating strategy which is transforming the pharmaceutical ecosystem, disrupting drug development and manufacturing technologies and providing major growth opportunities in high potency and biopharmaceuticals manufacturing.  Thus, providing for long-term profitability of CMOs at the global level.

These developments are thus, set to provide the biopharmaceutical contract manufacturing market with profitable prospects over the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Factors Restraining Demand for Biopharmaceutical Contract Manufacturing?

Biopharmaceuticals manufacturing capacity is one of the important factors in the growth of the market. Manufacturing of drugs in bulk volumes requires facilities to have large scale plants with huge capacity and big funding. Globally, biopharma companies have spent billions in just the past few years on new plants and equipment. Much of that has been in tax havens, like Ireland and Singapore, and in emerging markets. About a quarter of the projects have been in the US.

Additionally, development of a new plants takes nearly 4 years to design, build and qualify, while costing anywhere between US$ 250 million to US$ 2 billion, which is too high as compared to small scale pants and industries. Also, with availability of limited yet traditional facilities, it is not enough and also too old to develop any modern drugs. Thus, limited CMO facility together with the need for huge capital investment poses a major restraining factor for the growth of this market.

Another major factor impacting this market is the changing regulatory dynamics around the globe. Global regulatory policies, tightening regime of inspection and supply chain security related issues across countries impacts largely on the cost of final products and ultimately makes the market entry for new players a costly decision due to financial constraints along with the aforementioned factors.

The increasing complexity of biopharmaceuticals operations and the biopharmaceuticals supply chain has already stretched the current production programs across industries. Many players are thus, constantly failing to deliver to the market. All these factors are expected to hinder the growth of the biopharmaceutical contract manufacturing market over the forecast duration globally.

Country-wise Insights

What Makes the U.S. the Largest Market for Biopharmaceutical Contract Manufacturing?

The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period. The growth of this market is driven by the high corporate venture capital investments which are helping to advance biotechnology R&D, strong biologics pipeline fuelling the demand for the CMOs and establishment of key manufacturers & research institutes with dedicated programs for the contract manufacturing organizations.

Why is Germany Considered a Lucrative Market for Biopharmaceutical Contract Manufacturing?

Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option. Thus, more research and clinical trials in biopharmaceuticals to reduce the cost and focus on outsourcing of most research activities is raising the demand for biopharmaceutical contract manufacturing market in Germany.

What Makes China an Emerging Market for Biopharmaceutical Contract Manufacturing?

China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the biopharmaceutical contract manufacturing market in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth, including seeking the opportunities to collaborate/partner with the local organizations which is helping this region to emerge and grow over the forecast period.

What is the Outlook for India Regarding Biopharmaceutical Contract Manufacturing?

In 2021, India held a 30.4% share in the global Biopharmaceutical Contract Manufacturing market and is projected to expand at a CAGR of 11.9% from 2022 to 2029. India projects a significant growth in the global biopharmaceutical contract manufacturing market owing to increase in the investments in research and development area, expansion in the offerings of the services and increase in the outsourcing processes by different biopharmaceutical industries.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

Which Biopharmaceutical Contract Manufacturing Platform is Driving Market Growth?

Mammalian-based segment hold the largest market share of 72.8% in 2021 and is projected to grow over the forecast period, with CAGR of about 12.3% due to higher efficiency and less time-consuming effort. Mammalian based cell culture such as Chinese Hamster Ovary cells (CHO) and recombinant monoclonal antibodies have been used for the production of biopharmaceuticals in large quantities as compared to other platforms.

Which Biopharmaceutical Contract Manufacturing Product is Driving Market Growth?

Monoclonal Antibodies products project a lucrative growth at a CAGR of 11.6% till the end of the forecast period, with a market share of around 50.0% in 2021. Increasing prevalence of metabolic diseases and cancer is helping to increase the revenue share of the recombinant protein and insulin segment of the monoclonal antibodies due to increased usage in the research field.

Why is Commercial application being Widely Adopted Application in the Biopharmaceutical Contract Manufacturing Market?

Commercial application enjoys a revenue share of 78.7% in the global biopharmaceutical contract manufacturing market in 2021. Commercial segment revenue share is expected to increase further over the forecast duration with a growth rate of 10.9% due to the increasing biologic drugs demand and large scale up facility of contract manufacturing organizations.

Which Therapeutic Area is Largely of Focus in the Biopharmaceutical Contract Manufacturing Market?

Oncology holds a revenue share of 20.9% in 2021 and are projected to grow over the forecast period with CAGR of 13.6%. The segment holds the largest revenue share due to the increasing incidences and prevalence of the targeted diseases in the oncology segment all over the Globe. Additionally, large number of clinical research activities to develop new therapeutic options and involvement of large number of manufacturers introducing novel product lines in this field further adds to the growth of this market.

Competitive Landscape

Leading contract manufacturing organizations are focusing on geographical expansion to gain high revenue & expand their sales footprint in emerging countries by acquisition of local market players.

Strategic divestitures, collaborations, exclusive partnership agreements and research sponsorship are the key strategies adopted by manufacturers to increase the product sales in different geographies.

  • In 2021, Lonza Group Ag, disclosed its highest sale after selling Lonza Speciality Ingredients to Bain Capital Private Equity for $4.4B.
  • In November 2021, Abzena limited, a partner research organization for integrated discovery of cGMP and a manufacturer of biopharmaceuticals solutions collaborated with BiVictriX Therapeutics plc, a biotechnology company to manufacture the BiVictriX’s antibody-drug conjugates (ADC).
  • In September 2021 Novasep Company did an exclusive partnership with PharmaZell. The partnership is focussed to develop, manufacture and expand, complex small molecules and ADCs at a global scale.

Similarly, recent developments related to companies of biopharmaceuticals contract manufacturing have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as per Biopharmaceutical Contract Manufacturing Industry Analysis

Attribute

Details

Forecast Period

2022-2029

Historical Data Available for

2012-2021

Market Analysis

US$ Mn for Value

Key Regions Covered

North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan and Middle East & Africa

Key Countries Covered

US, Canada, Brazil, Mexico, Argentina, Germany, U.K., France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, North Africa, GCC Countries, Turkey, and South Africa

Key Market Segments Covered

Platform, Product, Application, Therapeutic area, and Region

Key Companies Profiled

  • Catalent Inc.
  • Lonza Group Ag
  • Patheon N.V. (Thermo Fisher Scientific Inc.)
  • Abzena Plc.
  • Sandoz International GmbH (Novartis AG)
  • Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
  • Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
  • AbbVie Contract Manufacturing (AbbVie Inc.)
  • Samsung Biologics Co. Ltd.
  • ProBioGen AG
  • Pfizer Centre Source Ltd (Pfizer Inc.)
  • Novasep
  • Biomeva GmbH
  • Kbi Biopharma Inc
  • Rentschler Biotechnologie GmbH
  • Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)

Pricing

Available upon Request

Key Market Segments Covered in Biopharmaceutical Contract Manufacturing Industry Research

By Platform Type:

  • Mammalian Based
  • Microbial Based

By Product Type:

  • Monoclonal Antibodies
  • Recombinant Protein
  • Vaccine
  • Insulin
  • Growth factor 
  • Interferons
  • Others

By Application Type:

  • Clinical
  • Commercial

By Therapeutic Area Type:

  • Autoimmune Diseases
  • Oncology
  • Metabolic Diseases
  • Ophthalmology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Neurology
  • Respiratory Disorders
  • Others

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global biopharmaceutical contract manufacturing market is worth US$ 9.28 Bn in 2021 and is estimated to grow 2 times over the forecast duration.

The biopharmaceutical contract manufacturing market is expected to reach US$ 18.65 Bn by the end of 2029, with sales revenue expected to register 10.5% CAGR.

Growing technical advancements, strategic research collaborations, acquisitions & expansion by outsourcing of biopharmaceuticals manufacturing and accelerating product adoption rate are some of the key trends being witnessed in this marketplace.

The U.S., China, India, Japan, Germany are expected to drive demand in biopharmaceutical contract manufacturing market.

North America is one of the key markets for biopharmaceutical contract manufacturing, with the U.S. expected to account for nearly 91.0% of the North American market during the forecast period.

Demand for biopharmaceutical contract manufacturing in Eastern Europe is expected to register growth of 10% over the next seven years.

Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), Baxter Pharmaceutical Solutions LLC (Baxter Inc.), AbbVie Contract Manufacturing (AbbVie Inc.), Samsung Biologics Co. Ltd. , ProBioGen AG , Pfizer Centre Source Ltd (Pfizer Inc.), Novasep , Biomeva GmbH, Kbi Biopharma Inc, Rentschler Biotechnologie GmbH and Ajinomoto Althea Inc., (Ajinomoto Co., Inc.) are the key

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. Analysis and Recommendations

2. Market Introduction

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Macro-Economic Factors

    3.2. Opportunity Analysis

    3.3. Regulatory Overview

4. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Opportunity Assessment, 2022-2029

    4.1. Historical Market Value (US$ Mn) Analysis, 2012-2021

    4.2. Current and Future Market Value (US$ Mn) Projections, 2022-2029

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Incremental Opportunity Analysis

        4.2.3. Market Value Comparison 

5. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Platform 

    5.1. Introduction / Key Findings

    5.2. Historical Market Size (US$ Mn) Analysis By Platform, 2012–2021

    5.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Platform, 2022-2029

        5.3.1. Mammalian

        5.3.2. Microbial

    5.4. Market Attractiveness Analysis By Platform

6. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Product 

    6.1. Introduction / Key Findings

    6.2. Historical Market Size (US$ Mn) Analysis By Product, 2012–2021

    6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2029

        6.3.1. Growth Factors

        6.3.2. Interferon’s

        6.3.3. Monoclonal Antibodies

        6.3.4. Recombinant Hormones

        6.3.5. Vaccines

        6.3.6. Insulin

        6.3.7. Others

    6.4. Market Attractiveness Analysis By Product

7. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Application

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Application, 2012–2021

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2029

        7.3.1. Clinical

        7.3.2. Commercial

    7.4. Market Attractiveness Analysis By Application

8. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Therapeutic Area

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2012–2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Area, 2022-2029

        8.3.1. Autoimmune Diseases

        8.3.2. Oncology

        8.3.3. Metabolic Diseases

        8.3.4. Ophthalmology

        8.3.5. Cardiovascular Diseases 

        8.3.6. Infectious Diseases 

        8.3.7. Neurology

        8.3.8. Respiratory Disorders 

        8.3.9. Others

    8.4. Market Attractiveness Analysis By Therapeutic Area

9. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029, by Region 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021

    9.3. Current and Future Market Size (US$ Mn) and Forecast By Region, 2022-2029

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. APEJ

        9.3.6. Japan

        9.3.7. Middle East & Africa 

    9.4. Market Attractiveness Analysis By Region

10. North America Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029

    10.1. Introduction

    10.2. Regional Market Dynamics

        10.2.1. Drivers

        10.2.2. Restraints 

        10.2.3. Trends

    10.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    10.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029

        10.4.1. By Country

            10.4.1.1. U.S.

            10.4.1.2. Canada

        10.4.2. By Platform

        10.4.3. By Product

        10.4.4. By Application

        10.4.5. By Therapeutic Area

    10.5. Market Attractiveness Analysis

        10.5.1. By Country

        10.5.2. By Platform

        10.5.3. By Product

        10.5.4. By Application

        10.5.5. By Therapeutic Area

    10.6. Key Market Participants - Intensity Mapping

11. Latin America Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029

    11.1. Introduction

    11.2. Regional Market Dynamics

        11.2.1. Drivers

        11.2.2. Restraints 

        11.2.3. Trends

    11.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    11.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029

        11.4.1. By Country

            11.4.1.1. Mexico

            11.4.1.2. Brazil

            11.4.1.3. Rest of Latin America

        11.4.2. By Platform

        11.4.3. By Product

        11.4.4. By Application

        11.4.5. By Therapeutic Area

    11.5. Market Attractiveness Analysis

        11.5.1. By Platform

        11.5.2. By Product

        11.5.3. By Application

        11.5.4. By Therapeutic Area

    11.6. Key Market Participants - Intensity Mapping

12. Western Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029

    12.1. Introduction

    12.2. Regional Market Dynamics

        12.2.1. Drivers

        12.2.2. Restraints 

        12.2.3. Trends

    12.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    12.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029

        12.4.1. By Country

            12.4.1.1. U.K.

            12.4.1.2. Germany

            12.4.1.3. France

            12.4.1.4. Italy

            12.4.1.5. Spain

            12.4.1.6. BENELUX

            12.4.1.7. Nordic

            12.4.1.8. Rest of Western Europe

        12.4.2. By Platform

        12.4.3. By Product

        12.4.4. By Application

        12.4.5. By Therapeutic Area

    12.5. Market Attractiveness Analysis

        12.5.1. By Country

        12.5.2. By Platform

        12.5.3. By Product

        12.5.4. By Application

        12.5.5. By Therapeutic Area

    12.6. Key Market Participants - Intensity Mapping

13. Eastern Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029

    13.1. Introduction

    13.2. Regional Market Dynamics

        13.2.1. Drivers

        13.2.2. Restraints 

        13.2.3. Trends

    13.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    13.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029

        13.4.1. By Country

            13.4.1.1. Russia

            13.4.1.2. Poland

            13.4.1.3. Rest of Eastern Europe

        13.4.2. By Platform

        13.4.3. By Product

        13.4.4. By Application

        13.4.5. By Therapeutic Area

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Platform

        13.5.3. By Product

        13.5.4. By Application

        13.5.5. By Therapeutic Area

    13.6. Key Market Participants - Intensity Mapping

14. APEJ Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029

    14.1. Introduction

    14.2. Regional Market Dynamics

        14.2.1. Drivers

        14.2.2. Restraints 

        14.2.3. Trends

    14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    14.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029

        14.4.1. By Country

            14.4.1.1. China

            14.4.1.2. India

            14.4.1.3. Australia & New Zealand

            14.4.1.4. ASEAN

            14.4.1.5. South Korea

            14.4.1.6. Rest of APEJ

        14.4.2. By Platform

        14.4.3. By Product

        14.4.4. By Application

        14.4.5. By Therapeutic Area

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Platform

        14.5.3. By Product

        14.5.4. By Application

        14.5.5. By Therapeutic Area

    14.6. Key Market Participants - Intensity Mapping

15. Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029

    15.1. Introduction

    15.2. Regional Market Dynamics

        15.2.1. Drivers

        15.2.2. Restraints 

        15.2.3. Trends

    15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    15.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029

        15.4.1. By Platform

        15.4.2. By Product

        15.4.3. By Application

        15.4.4. By Therapeutic Area

    15.5. Market Attractiveness Analysis

        15.5.1. By Platform

        15.5.2. By Product

        15.5.3. By Application

        15.5.4. By Therapeutic Area

    15.6. Key Market Participants - Intensity Mapping

16. Middle East and Africa Biopharmaceutical Contract Manufacturing Market Analysis 2012-2021 and Forecast 2022-2029

    16.1. Introduction

    16.2. Regional Market Dynamics

        16.2.1. Drivers

        16.2.2. Restraints 

        16.2.3. Trends

    16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    16.4. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029

        16.4.1. By Country

            16.4.1.1. GCC Countries

            16.4.1.2. Turkey

            16.4.1.3. North Africa

            16.4.1.4. South Africa

            16.4.1.5. Rest of Middle East & Africa

        16.4.2. By Platform

        16.4.3. By Product

        16.4.4. By Application

        16.4.5. By Therapeutic Area

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Platform

        16.5.3. By Product

        16.5.4. By Application

        16.5.5. By Therapeutic Area

    16.6. Key Market Participants - Intensity Mapping

17. Competition Landscape

    17.1. Competition Dashboard

    17.2. Company Deep Dive

        17.2.1. Catalent Inc. 

            17.2.1.1. Overview

            17.2.1.2. Product Overview

            17.2.1.3. Key Financials

            17.2.1.4. Key Developments

            17.2.1.5. SWOT Analysis

            17.2.1.6. Strategic Overview

        17.2.2. Lonza Group Ag

            17.2.2.1. Overview

            17.2.2.2. Product Overview

            17.2.2.3. Key Financials

            17.2.2.4. Key Developments

            17.2.2.5. SWOT Analysis

            17.2.2.6. Strategic Overview

        17.2.3. Patheon N.V. (Thermo Fisher Scientific Inc.)

            17.2.3.1. Overview

            17.2.3.2. Product Overview

            17.2.3.3. Key Financials

            17.2.3.4. Key Developments

            17.2.3.5. SWOT Analysis

            17.2.3.6. Strategic Overview

        17.2.4. Abzena Plc. 

            17.2.4.1. Overview

            17.2.4.2. Product Overview

            17.2.4.3. Key Financials

            17.2.4.4. Key Developments

            17.2.4.5. SWOT Analysis

            17.2.4.6. Strategic Overview

        17.2.5. Sandoz International GmbH (Novartis AG)

            17.2.5.1. Overview

            17.2.5.2. Product Overview

            17.2.5.3. Key Financials

            17.2.5.4. Key Developments

            17.2.5.5. SWOT Analysis

            17.2.5.6. Strategic Overview

        17.2.6. Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)

            17.2.6.1. Overview

            17.2.6.2. Product Overview

            17.2.6.3. Key Financials

            17.2.6.4. Key Developments

            17.2.6.5. SWOT Analysis

            17.2.6.6. Strategic Overview

        17.2.7. Baxter Pharmaceutical Solutions LLC (Baxter Inc.)

            17.2.7.1. Overview

            17.2.7.2. Product Overview

            17.2.7.3. Key Financials

            17.2.7.4. Key Developments

            17.2.7.5. SWOT Analysis

            17.2.7.6. Strategic Overview

        17.2.8. AbbVie Contract Manufacturing (AbbVie Inc.)

            17.2.8.1. Overview

            17.2.8.2. Product Overview

            17.2.8.3. Key Financials

            17.2.8.4. Key Developments

            17.2.8.5. SWOT Analysis

            17.2.8.6. Strategic Overview

        17.2.9. Samsung Biologics Co. Ltd.

            17.2.9.1. Overview

            17.2.9.2. Product Overview

            17.2.9.3. Key Financials

            17.2.9.4. Key Developments

            17.2.9.5. SWOT Analysis

            17.2.9.6. Strategic Overview

        17.2.10. ProBioGen AG

            17.2.10.1. Overview

            17.2.10.2. Product Overview

            17.2.10.3. Key Financials

            17.2.10.4. Key Developments

            17.2.10.5. SWOT Analysis

            17.2.10.6. Strategic Overview

        17.2.11. Pfizer Centre Source Ltd (Pfizer Inc.)

            17.2.11.1. Overview

            17.2.11.2. Product Overview

            17.2.11.3. Key Financials

            17.2.11.4. Key Developments

            17.2.11.5. SWOT Analysis

            17.2.11.6. Strategic Overview

        17.2.12. Novasep

            17.2.12.1. Overview

            17.2.12.2. Product Overview

            17.2.12.3. Key Financials

            17.2.12.4. Key Developments

            17.2.12.5. SWOT Analysis

            17.2.12.6. Strategic Overview

        17.2.13. Biomeva GmbH

            17.2.13.1. Overview

            17.2.13.2. Product Overview

            17.2.13.3. Key Financials

            17.2.13.4. Key Developments

            17.2.13.5. SWOT Analysis

            17.2.13.6. Strategic Overview

        17.2.14. Kbi Biopharma Inc

            17.2.14.1. Overview

            17.2.14.2. Product Overview

            17.2.14.3. Key Financials

            17.2.14.4. Key Developments

            17.2.14.5. SWOT Analysis

            17.2.14.6. Strategic Overview

        17.2.15. Rentschler Biotechnologie GmbH

            17.2.15.1. Overview

            17.2.15.2. Product Overview

            17.2.15.3. Key Financials

            17.2.15.4. Key Developments

            17.2.15.5. SWOT Analysis

            17.2.15.6. Strategic Overview 

        17.2.16. Ajinomoto Althea Inc. (Ajinomoto Co., Inc.)

            17.2.16.1. Overview

            17.2.16.2. Product Overview

            17.2.16.3. Key Financials

            17.2.16.4. Key Developments

            17.2.16.5. SWOT Analysis

            17.2.16.6. Strategic Overview

18. Assumption and Acronyms Used

19. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Growth Comparison

Table 02: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type

Table 03: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Product

Table 04: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis- and Opportunity Assessment 2012–2029, By Application

Table 05: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis- and Opportunity Assessment 2012–2029, By Therapeutic Area

Table 06: Global Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Region

Table 07: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 08: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type

Table 09: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product

Table 10: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area

Table 11: North America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 12: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 13: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type

Table 14: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product

Table 15: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area

Table 16: Latin America Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 17: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 18: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type

Table 19: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product

Table 20: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area

Table 21: Western Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 22: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 23: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type

Table 24: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product

Table 25: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area

Table 26: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 27: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 28: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type

Table 29: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product

Table 30: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area

Table 31: APEJ Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 32: Japan Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 33: Japan Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type

Table 34: Japan Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product

Table 35: Japan Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area

Table 36: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 37: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis and Opportunity Assessment 2012–2029, By Platform Type

Table 38: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Product

Table 39: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Therapeutic Area

Table 40: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Biopharmaceutical Contract Manufacturing Market Revenue Share by Platform, 2022E & 2029F

Figure 2: Biopharmaceutical Contract Manufacturing Market Revenue Share by Application, 2022E & 2029F

Figure 3: Biopharmaceutical Contract Manufacturing Market Revenue Share by Product, 2022E & 2029F

Figure 4: Biopharmaceutical Contract Manufacturing Market Revenue Share by Therapeutic Area, 2022E & 2029F

Figure 05: Global Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021

Figure 06: Global Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029

Figure 07: Global Biopharmaceutical Contract Manufacturing Market Absolute $ Opportunity, 2022 - 2029

 Figure 08: Comparison August 2017 and December 2022, Y-o-Y Forecast

Figure 09: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Platform Type, 2022 & 2029

Figure 10: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Platform Type, 2022-2029

Figure 11: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029 

Figure 12: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Product, 2022 & 2029

Figure 13: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Product, 2022-2029

Figure 14: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029 

Figure 15: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Application, 2022 & 2029

Figure 16: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Application, 2022-2029

Figure 17: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029 

Figure 18: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Therapeutic Area, 2022 & 2029

Figure 19: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Therapeutic Area, 2022-2029

Figure 20: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029 

Figure 21: Global Biopharmaceutical Contract Manufacturing Market Share Analysis (%), By Region, 2022 & 2029

Figure 22: Global Biopharmaceutical Contract Manufacturing Market Y-o-Y Analysis (%), By Region, 2022-2029

Figure 23: Global Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Region, 2022-2029

Figure 24: North America Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)

Figure 25: North America Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)

Figure 26: North America Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)

Figure 27: North America Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)

Figure 28: North America Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)

Figure 29: North America Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021

Figure 30: North America Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029

Figure 31: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029

Figure 32: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029 

Figure 33: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029 

Figure 34: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029 

Figure 35: North America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029 

Figure 36: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)

Figure 37: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)

Figure 38: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)

Figure 39: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)

Figure 40: Latin America Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)

Figure 41: Latin America Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021

Figure 42: Latin America Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029

Figure 43: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029

Figure 44: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029 

Figure 45: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029 

Figure 46: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029 

Figure 47: Latin America Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029 

Figure 48: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)

Figure 49: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)

Figure 50: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)

Figure 51: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)

Figure 52: Western Europe Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)

Figure 53: Western Europe Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021

Figure 54: Western Europe Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029

Figure 55: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029

Figure 56: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029 

Figure 57: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029 

Figure 58: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029 

Figure 59: Western Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029 

Figure 60: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)

Figure 61: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)

Figure 62: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)

Figure 63: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)

Figure 64: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)

Figure 65: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021

Figure 66: Eastern Europe Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029

Figure 67: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029

Figure 68: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029 

Figure 69: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029 

Figure 70: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029 

Figure 71: Eastern Europe Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029 

Figure 72: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)

Figure 73: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)

Figure 74: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)

Figure 75: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)

Figure 76: APEJ Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)

Figure 77: APEJ Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021

Figure 78: APEJ Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029

Figure 79: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029

Figure 80: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029 

Figure 81: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029 

Figure 82: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029 

Figure 83: APEJ Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029 

Figure 84: Japan Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)

Figure 85: Japan Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)

Figure 86: Japan Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)

Figure 87: Japan Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)

Figure 88: Japan Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021

Figure 89: Japan Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029

Figure 90: Japan Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029

Figure 91: Japan Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029 

Figure 92: Japan Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029 

Figure 93: Japan Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029 

Figure 94: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Application (2022E)

Figure 95: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Platform Type (2022E)

Figure 96: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Product (2022E)

Figure 97: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Therapeutic Area (2022E)

Figure 98: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Share by Country (2022E)

Figure 99: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Analysis (US$ Mn), 2012-2021

Figure 100: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Value Forecast (US$ Mn), 2022-2029

Figure 101: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Platform Type, 2022-2029

Figure 102: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Application, 2022-2029 

Figure 103: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Product, 2022-2029 

Figure 104: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Therapeutic Area, 2022-2029 

Figure 105: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Attractiveness Analysis by Country, 2022-2029

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

CMO/CDMO Market

Published : March 2021

Healthcare

Biologics Contract Manufacturing Market

Published : January 2017

Healthcare

Pharmerging Contract Manufacturing Market

Published : December 2016

Google translate

Biopharmaceutical Contract Manufacturing Market